Regulatory Pathways for Novel Diagnostics: PMDA, FDA, and IVDR Compared | Policy & Market Intelligence

Description

List of Tables

A diagnostics company launching a novel test today faces three regulatory systems moving in opposite directions at once. In Europe, the IVDR transition deadlines are arriving in waves from 2027 to 2029, and the compliance burden has already pushed a substantial share of manufacturers to trim their EU portfolios - a supply contraction with few precedents in the industry's history. In the United States, the vacatur of the FDA's laboratory-developed test rule has thrown the kit-versus-service business-model question back open, reshaping how novel diagnostics reach American patients. In Japan, the PMDA pathway runs on its own logic, and its distinctive feature is the linkage between approval category and the C2 reimbursement designation that determines whether an approved test can actually be sold at scale.

For a regulatory team, the practical problem is sequencing and leverage: which jurisdiction first, which dossier elements transfer, and where the same clinical evidence can be used twice. The systems classify risk differently, demand different analytical and clinical validation packages, and handle software, companion diagnostics, and novel biomarkers through different mechanisms. A submission strategy optimized for one market can actively damage the others.

This report provides a working comparison of the PMDA, FDA, and IVDR pathways for novel diagnostics. It opens with the structural anatomy of each system - classification, review routes, notified-body and review-capacity constraints, and post-market obligations - and then works through the categories that matter most for novel tests: companion diagnostics, NGS panels, novel protein biomarkers, AI-integrated assays, and self-sampling configurations. Case chapters trace how specific products navigated each regime, including the kit-versus-service repositioning forced by the LDT vacatur and the Japanese C2 linkage cases. Company coverage spans the diversified IVD majors - Roche, Abbott, Siemens Healthineers, Danaher, bioMerieux, Qiagen, BD, DiaSorin - alongside Japanese filers such as Sysmex and Fujirebio and the Chinese entrants Mindray, Wondfo, and Snibe now building EU and US registration portfolios. The report answers where each pathway is fastest, where it is cheapest, what evidence transfers, and how to sequence a three-region filing plan.

The report is written for regulatory leadership at IVD companies, startups planning first Japan entry, and investors diligence-ing regulatory risk. An annual update tracks IVDR deadline waves, FDA guidance, and PMDA fee and review changes.

Scope and Coverage: The report compares diagnostic regulatory pathways across Japan (PMDA), the US (FDA), and the EU (IVDR) for novel IVDs, covering classification, review routes, evidence requirements, reimbursement linkage, and post-market rules, with China addressed as an origin market. It is an intelligence product, not legal advice.

Report Highlights:

Side-by-side anatomy of PMDA, FDA, and IVDR classification and review systems
IVDR transition deadline waves (2027-2029) and portfolio-trimming consequences
US LDT vacatur analysis and the kit-versus-service model decision framework
Japan C2 reimbursement linkage and its effect on commercial sequencing
Case studies across companion diagnostics, NGS panels, and novel biomarker assays
Company regulatory footprints including Roche, Abbott, Siemens Healthineers, Sysmex, Fujirebio, Mindray, and Guardant Health

Product Code: JPH-062

Table of Content

1. Executive Summary

2. Regulatory Pathways for Novel Diagnostics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Roche (CH) - diversified IVD maker, IVDR transition and PMDA reference case
Abbott (US) - diagnostics portfolio spanning core lab to POCT, Exact Sciences acquisition (Mar 2026)
Siemens Healthineers (DE) - Atellica platform, IVDR certificate holder
Danaher (US) - Beckman Coulter and Cepheid under one regulatory organization
bioMerieux (FR) - microbiology and syndromic IVD specialist navigating IVDR
Mindray (CN) - Chinese IVD maker pursuing EU and US registrations
Qiagen (DE) - molecular IVD with IVDR-certified QIAstat and QuantiFERON lines
Becton Dickinson (US) - BD MAX and microbiology regulatory footprint
DiaSorin (IT) - specialty immunodiagnostics under IVDR
Sysmex (JP) - Japanese IVD maker with FDA, IVDR, and PMDA filings across regions
Fujirebio (JP) - neuro-IVD specialist (Lumipulse), CE-marked NfL (Mar 2026)
Thermo Fisher (US) - Oncomine CDx lineage across PMDA, FDA, and IVDR
Guardant Health (US) - kit-vs-service model case study after the US LDT vacatur
Wondfo (CN) - Chinese POCT maker with IVDR registrations
Snibe (CN) - Chinese immunoassay maker expanding EU registrations

Product Code: JPH-062

List of Tables

Table 1. PMDA IVD classification structure and risk classes
Table 2. PMDA review routes: premarket approval, certification, and notification
Table 3. FDA IVD classification and 510(k), De Novo, and PMA routes
Table 4. IVDR classification rules and conformity assessment routes
Table 5. IVDR transition deadline waves (2027-2029) by class
Table 6. Notified-body capacity constraints under IVDR
Table 7. Manufacturer EU portfolio reductions during IVDR transition
Table 8. US LDT rule vacatur and its business-model consequences
Table 9. Kit-versus-service model decision factors after the LDT vacatur
Table 10. Japan C2 reimbursement designation linkage to approval categories
Table 11. Roche IVDR transition and PMDA filing reference case
Table 12. Abbott diagnostics portfolio regulatory footprint and Exact Sciences acquisition (March 2026)
Table 13. Siemens Healthineers Atellica platform IVDR certificate status
Table 14. Danaher Beckman Coulter and Cepheid regulatory organization
Table 15. bioMerieux microbiology and syndromic portfolio under IVDR
Table 16. Qiagen QIAstat and QuantiFERON IVDR certification status
Table 17. Becton Dickinson BD MAX and microbiology regulatory footprint
Table 18. DiaSorin specialty immunodiagnostics under IVDR
Table 19. Sysmex cross-region filing portfolio across FDA, IVDR, and PMDA
Table 20. Fujirebio Lumipulse regulatory lineage and CE-marked NfL (March 2026)
Table 21. Thermo Fisher Oncomine CDx lineage across PMDA, FDA, and IVDR
Table 22. Guardant Health kit-versus-service repositioning after the LDT vacatur
Table 23. Mindray EU and US registration program
Table 24. Wondfo IVDR registration portfolio
Table 25. Snibe EU registration expansion
Table 26. Companion diagnostic regulatory pathways across the three regions
Table 27. NGS panel regulatory treatment across the three regions
Table 28. Novel protein biomarker evidence requirements by region
Table 29. AI-integrated assay regulatory treatment by region
Table 30. Self-sampling configuration regulatory treatment by region
Table 31. Analytical validation requirements comparison
Table 32. Clinical validation requirements comparison
Table 33. Clinical evidence transferability between dossiers
Table 34. Japanese-language dossier and in-country requirements
Table 35. Foreign-manufacturer accreditation and MAH structures in Japan
Table 36. Review timeline expectations by pathway and region
Table 37. Registration cost structures by pathway and region
Table 38. Post-market surveillance obligations comparison
Table 39. Software and SaMD rules intersecting IVD regulation
Table 40. Laboratory-developed test treatment across the three regions
Table 41. Companion diagnostic co-development sequencing with drug approvals
Table 42. Three-region filing sequencing frameworks
Table 43. Regulatory intelligence sources and monitoring requirements
Table 44. PMDA consultation programs for novel diagnostics
Table 45. FDA pre-submission and breakthrough device programs
Table 46. IVDR orphan and special-purpose provisions
Table 47. Change-management rules for approved assays by region
Table 48. Scenario framework for IVDR implementation outcomes
Table 49. Regulatory risk checklist for investors
Table 50. Report methodology and annual update design

List of Figures

Figure 1. Three-region regulatory system map for novel diagnostics
Figure 2. PMDA IVD review route decision tree
Figure 3. FDA IVD review route decision tree
Figure 4. IVDR conformity assessment route decision tree
Figure 5. IVDR transition timeline by class (2027-2029)
Figure 6. Notified-body capacity bottleneck structure
Figure 7. EU portfolio-trimming mechanism during IVDR transition
Figure 8. US LDT vacatur decision framework
Figure 9. Kit-versus-service model comparison
Figure 10. Japan approval-to-C2-reimbursement linkage diagram
Figure 11. Roche three-region regulatory footprint
Figure 12. Abbott regulatory organization including Exact Sciences integration
Figure 13. Siemens Healthineers Atellica IVDR certification structure
Figure 14. Danaher diagnostics regulatory organization
Figure 15. bioMerieux IVDR navigation map
Figure 16. Qiagen IVDR-certified product lines
Figure 17. BD regulatory footprint across molecular and microbiology
Figure 18. DiaSorin specialty immunodiagnostics pathway map
Figure 19. Sysmex cross-region filing architecture
Figure 20. Fujirebio neuro-IVD regulatory lineage
Figure 21. Thermo Fisher Oncomine CDx lineage across regions
Figure 22. Guardant Health business-model repositioning map
Figure 23. Mindray registration expansion pathway
Figure 24. Chinese IVD makers' EU and US entry routes
Figure 25. Companion diagnostic pathway comparison
Figure 26. NGS panel regulatory treatment comparison
Figure 27. Novel biomarker evidence requirement map
Figure 28. AI-integrated assay treatment comparison
Figure 29. Self-sampling configuration treatment comparison
Figure 30. Analytical validation requirement comparison
Figure 31. Clinical validation requirement comparison
Figure 32. Dossier transferability map between regions
Figure 33. Japanese in-country requirement structure
Figure 34. Foreign-manufacturer and MAH structure diagram
Figure 35. Review timeline comparison by pathway
Figure 36. Registration cost structure comparison
Figure 37. Post-market surveillance obligation map
Figure 38. Software rule intersection with IVD regulation
Figure 39. LDT treatment comparison across regions
Figure 40. CDx co-development sequencing with drug approval
Figure 41. Three-region filing sequencing framework
Figure 42. Regulatory intelligence monitoring architecture
Figure 43. PMDA consultation program structure
Figure 44. FDA pre-submission program structure
Figure 45. IVDR special provisions map
Figure 46. Change-management rule comparison
Figure 47. Scenario tree for IVDR implementation
Figure 48. Regulatory risk heat map for novel diagnostics
Figure 49. Evidence-package reuse framework across regions
Figure 50. Report scope, method, and annual update design

Regulatory Pathways for Novel Diagnostics: PMDA, FDA, and IVDR Compared | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Regulatory Pathways for Novel Diagnostics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures